6 Nov 2017 BAARN (Boston Area Antimicrobial Resistance Network) + 7-8 Nov BARDA Industry Days

Dear All:

Early November will be busy! First, BAARN is having their annual meeting in the Boston area on 6 Nov. See below a note from Michael Gilmore with details. If you are in Boston on that day, I highly recommend this meeting as a superb scientific event & networking opportunity.

Second, you can then go from BAARN to BARDA’s Industry Days in DC on 7-8 Nov. Here’s the registration link for more details. This is an opportunity to learn about BARDA’s strategic goals for FY18 and beyond while networking with members of ASPR, BARDA, AMCG and other government and industry stakeholders. If you are consider US government funding, this is a great way to learn about working with BARDA and its USG partners.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Mike writes: Tickets for the 2017 annual Boston Area Antibiotic Resistance Network meeting are now available at this link. The event will be on 6 Nov 2017 at the American Academy of Arts and Science’s Norton Woods Conference Center, adjacent to the Harvard campus (200 Beacon St., Somverville MA). The auditorium is limited to 200 attendees, so register early and notify friends and associates you know to be interested.

In response to feedback from last year, there will be more opportunity for 1-on-1 networking throughout the day. There will also be a rapid fire session for new biotechs to introduce their new efforts to the community.

The program:
8:00 – 8:30 Registration
8:30  Welcome

8:35 Session I: Advances in new therapeutics
10:15 – 11:00 Networking over coffee

11:00  Session II: Advances in alternatives to antibiotics for managing host microbe interactions
12:15 Lunch and more networking

2:00  Session III: Advances in Diagnostics
3:40 – 4:00 Short Break

4:00  Federal resources that can help (NIH Research Resources & Translational. Research DMID)
4:30  Short poster pitches from select treatment or diagnostic biotech startups

5:15 Networking and posters
7:00 Adjourn

​——————————
Upcoming meetings of interest to the AMR community:

Share

ENABLE-2 funding now includes Hit Identification & Validation

Dear All, I wrote on 25 Aug 2023 about the ENABLE-2 program and its support for hit-to-lead compound development. As a reminder, that program is focused on molecules with the potential to be direct-acting therapies for one or more of the following priority pathogens: ESBL-producing/carbapenem-resistant Enterobacteriaceae (E. coli, K. pneumoniae), P. aeruginosa, A. baumannii, methicillin-resistant S. aureus, or vancomycin-resistant E. faecium. Adding to that program, there is now an ENABLE-2

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

The (confusing!) language of AMR: ChatGPT tries to help!

Dear All (Wonkish alert! Not technical but lengthy … so settle in and enjoy the ride!): Regular readers will know of my fascination with language: e.g., this 20 Feb 2020 newsletter entitled “Language Matters: CRE vs. CPE; SDD vs. I; And MDR, XDR, PDR, UDR vs. DTR.” How about that for acronymics taken to Olympian

Scroll to Top